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Abstract 
Problem: Up to 29% of those with a mental illness are readmitted to a psychiatric hospital 
within 30 days. Hospital readmissions to inpatient psychiatric hospitals are costly, averaging 
$7,200 per readmission. Major challenges of inpatient psychiatric care are nonadherence to 
medication and transition of follow-up care upon discharge. Further limitations are experienced 
when the patient is without health insurance and can result in a cycle of repeated psychiatric 
admissions. 
Project Aim: The Donabedian Model guided the primary aim of this Quality Improvement (QI) 
project which was to determine if a Discharge Medication Assistance Program (DMAP) at 
CoxHealth in Springfield, Missouri reduced the 30-day readmission rates on three inpatient 
psychiatric units. 
Project Method: A retrospective analysis of discharge and 30-day readmission data from 
January 2018 through June 2018.  
Findings:  Patients discharged on DMAP had 12% lower readmission rates than those not on 
DMAP. 
Clinical Implications:  Psychiatric programs that provide medications to patients at discharge 
can reduce 30-day readmission rates.  
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Evaluation of a Discharge Medication Assistance Program (DMAP) to Reduce Psychiatric 
Readmissions 
 Hospital readmissions are costly problems that result from both environmental barriers 
and underlying inadequacies in discharge treatment planning, especially in those who have 
psychiatric illnesses (Kalseth, Lassemo, Wahlbeck, Haaramo, & Magnussen, 2016). Financial 
stress, occurrence of mental health and substance abuse disorders, medication nonadherence, and 
housing instability are among the leading risk factors for hospital readmissions among patients 
with Medicaid (Jiang et al, 2016). Providing uninsured, high-risk patients the opportunity to 
obtain their prescribed psychotropic medications upon discharge can help decrease psychiatric 
readmissions (Tomko, Ahmed, Mukherjee, Roma, Dilucente, & Orchowski, 2013).  
Statement of Problem 
According to the Centers for Disease Control and Prevention (CDC) (2017a), 86% of the 
country’s $2.7 trillion annual healthcare costs are from chronic medical and mental health 
conditions. Nonadherence is a common contributor to avoidable health care costs, representing 
3% to 10% of total United States (US) health care expenses (Iuga & McGuire, 2014). 
Furthermore, approximately 125,000 deaths occur annually due to nonadherence to treatment 
plans (Bosworth et al., 2011). Mental health problems affect 18.5% of the US population 
(National Alliance on Mental Illness, 2019) and up to 12.2% of individuals with mental health 
diagnoses are uninsured (Mental Health America, 2019). Psychotropic medications are thought 
to be 75% effective when taken as prescribed (Sparks, 2015), however, when the affordability of 
medications is a factor, nonadherence is likely to be the result. 
Nonadherence in treatment plans and/or medications often leads to emergencies, resulting 
in emergency room (ER) visits. The number of ER visits involving psychiatric complaints is 5 
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million per year (CDC, 2017b). More than 20% of all patients who presented to the ER that were 
hospitalized reported to be non-adherent with their medications at time of admission, with 
covariates including age, payment source, and primary diagnosis (Heaton, Tundia, & Luder, 
2013). Medication adherence is an important problem that needs to be addressed and which 
would likely reduce hospital readmissions. Although there are several factors required to help an 
individual become or remain stable upon discharge from an inpatient psychiatric unit, ensuring 
patients have their prescribed medications may be a missing link to effective discharge planning. 
Medication assistance upon discharge could furthermore reduce readmission rates, especially for 
those patients who are uninsured.  
Background and Significance of Problem 
In 2016, 8.6% of Americans were uninsured, which fell from 9.1% in 2015 (U.S. Census 
Bureau, 2017). While the number of uninsured Americans continues to decrease, approximately 
12.2% of adults with mental illnesses remain uninsured (Mental Health America, 2019). Despite 
not having health insurance, many patients will seek medical attention when needed. US 
hospitals provide the majority of uncompensated care. According to the American Hospital 
Association (AHA) (2018), as of 2016, the cost of uncompensated care accounted for $38.8 
billion, up from $35.7 billion in 2015. 
Many barriers to mental health care result in increased ER visits and psychiatric 
hospitalizations. Approximately 10% of patients who visit the ER have a diagnosed psychiatric 
illness. Furthermore, it is estimated that 45% of patients who present to the ER with a mental 
health symptom have not been diagnosed with a psychiatric diagnosis (Zun, 2016). The cost of 
ER visits vary based on treatments completed, with an average cost ranging from $1,233 to 
$2,168 (Caldwell, Srebotnjak, Wang, & Hsia, 2013), not to mention the cost of an inpatient 
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psychiatric hospitalization, if warranted. Common barriers to treatment that can result in ER 
visits include financial strains, difficulty finding a primary care provider, lack of transportation, 
and embarrassment of having a psychiatric diagnosis (Abar, Holub, Lee, DeRienzo, & Nobay, 
2017). Furthermore, visits involving psychiatric complaints are causing overcrowding in many 
ERs. Increased boarding times in the ERs are a result of limited psychiatric resources and 
increased demand for inpatient psychiatric placements (Hamilton et al., 2016). 
Once admitted to a psychiatric unit, the multidisciplinary team typically includes a 
variety of consultants and providers (i.e., psychiatrists, mental health nurses, social workers, 
pharmacists, occupational and recreational therapists). These teams work in tandem to create an 
individualized treatment plan for each patient (Mattinson & Cheeseman, 2018). Nonadherence to 
pharmacological and therapeutic plans commonly results in decreased success rate of treatment, 
increased morbidity, and increased healthcare costs (Virgolesi et al., 2017). As nonadherence 
accounts for 20 to 60% of this patient population, a common focus of inpatient hospitalizations is 
medication education (Mert, Turgut, Kelleci, & Semiz, 2015). 
Planning for discharge follow-up during the acute hospitalization is important not only to 
decrease hospital readmissions, but also for management of symptoms. Follow-up planning 
commonly includes scheduling outpatient appointments (Smith et al., 2017) and making referrals 
for therapy, such as psychotherapy, family psychoeducation, and pharmacotherapy (Brunette et 
al., 2016). Establishing transition to substance abuse treatment centers is also facilitated when 
appropriate (Reif, Acevedo, Garnick, & Fullerton, 2017). Unfortunately, only 30% of those 
discharged from inpatient facilities are adherent to their outpatient follow-up plan (Roque, 
Findlay, Okoli, & El-Mallakh, 2017). When discharged from an inpatient psychiatric hospital, 
the chance of a readmission within 30 days is approximately 29% (Heslin & Weiss, 2015). 
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Therefore, it is important for the interdisciplinary team to ensure resources upon discharge are 
being completed to reduce the “revolving door” effect.  
Since readmission rates to inpatient psychiatric units are high and expensive, research to 
reduce psychiatric readmissions must focus on a variety of programs. One intervention found 
useful to reduce readmissions is medication education (Hume & Tomsik, 2014). Postal 
appointment reminders (Habit, Johnson, & Edlund, 2018) and follow-up telephone calls 
(Marcus, Hautala, & Allaudeen, 2018) are other interventions used. Still another intervention is a 
combination of home visits and follow-up telephone calls (Malakouti et al., 2016). Finally, 
access to patient navigators and assertive community treatment (ACT) teams following discharge 
decrease readmission rates (Akerle, et al., 2017). However, research is limited regarding the 
barriers uninsured patients face in efforts to obtain their medications upon discharge from the 
hospital. Patients with mental illnesses are at high risk for hospital readmissions due to the 
probability of having comorbidities, including diabetes and heart disease (Gopalan, 2018).  
Purpose 
The purpose of this quality improvement (QI) project was to determine if a Discharge 
Medication Assistance Program (DMAP) at CoxHealth in Springfield, Missouri reduced the 30-
day readmission rates on three inpatient psychiatric units. 
Discharge Medication Assistance Program (DMAP) at CoxHealth 
 In 2013, development of a psychiatric discharge medication assistance program (DMAP) 
was proposed at CoxHealth (D. Harbin, Administrative Director of Psychiatric Services, personal 
communication, June 27, 2018). The purpose of DMAP is to provide a 30-day supply of 
discharge medications for those patients who lack health insurance. The source of funding for 
DMAP is primarily grants and donations from CoxHealth. Knowing that individuals who have 
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limited finances and lack of insurance coverage are high risk for readmissions, the goal of the 
program was estimated to reduce both psychiatric and medical readmissions by 20%. The aim of 
the program was to make the transition to aftercare easier for the patient by providing a 30-day 
filled prescription to those who qualified for DMAP (D. Harbin, personal communication, June 
27, 2018). 
At CoxHealth, readmission is defined when an individual returns to the hospital after 30 
days of discharge from a CoxHealth facility. Exceptions to this definition are individuals who 
left against medical advice, mortalities, length of stay greater than one year, transfers to other 
acute-care facilities, chemotherapy visits, radiotherapy visits, those readmitted for dialysis, 
rehabilitation visits, and elective or planned admissions (D. Parrish, CoxHealth Business 
Analyst, personal communication, September 18, 2018). Prior to initiating DMAP in 2013, 
approximately 16.5% of all admissions to CoxHealth were readmissions. However, according to 
D. Harbin, it was suspected that this number was underreported and may actually have been 
closer to 20 to 25% (personal communication, June 27, 2018). The expense of providing 30-days 
worth of medications at no cost was thought to save CoxHealth more than the expense of a 
readmission according to D. Harbin (personal communication, June 27, 2018).  
 Staff psychiatrists prescribe medications on the DMAP formulary for those who qualify. 
In order to qualify for the DMAP, a patient must have no health insurance, be ineligible for 
Medicaid and fall 200% or less below the federal poverty level. When a patient is ready for 
discharge, social workers determine if the patient qualifies for DMAP by completing the DMAP 
form (Appendix A). The medications not covered on the DMAP include controlled substances, 
over-the-counter medications, or pre-admission medications. Furthermore, individuals may only 
utilize DMAP once every 90 days for a total of three times in a lifetime and can only receive up 
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to a 30-day supply of the medication. The exception is antibiotics, which can be filled in full. All 
alternative resources, such as online coupons and generic substations, are utilized prior to using 
the DMAP funds. In cases when a patient is not eligible for Medicaid, caseworkers provide 
DMAP and assist patients with a Medicaid application. All patients who receive DMAP are 
provided with an outpatient referral for ongoing medication follow-up. 
The DMAP formulary (Appendix B) consists of both medical and psychiatric 
medications provided through the CoxHealth Pharmacy. The DMAP medications are at a set co-
pay, and discounted to those who qualify, to either a $5 co-pay per prescription, or a $30 co-pay 
per prescription. CoxHealth pays for these co-pays; therefore, patients discharged on DMAP do 
not pay anything for the program (D. Harbin, personal communication, June 27, 2018). 
 DMAP participation is completely voluntary. If the individual opts into the program, the 
DMAP forms are completed by the social worker and the prescriptions and DMAP form are 
faxed to the CoxHealth Pharmacy for the medications to be filled. The patient completes the 
discharge process with the nurse and psychiatric technicians. The nurse discharging the patient 
provides medication education related to the DMAP medications, including reason for taking the 
medication(s), dosage amounts, and times to take the medication(s), along with management of 
possible side effects. When the patient has completed the discharge process, they are directed to 
the pharmacy where they pick up their prescribed medications (D. Harbin, personal 
communication, June 27, 2018). Since it’s inception, the DMAP program has never been 
evaluated for its ability to reduce readmissions, thus, the need for this study. 
Methods for Literature Review 
Databases used for this literature search included Cochrane Databases, MEDLINE, 
PsychINFO, PubMed, CINAHL, and Google Search. Keywords included mental health, 
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psychiatry, psych*, discharge planning, discharge programs, hospital discharge, readmission, 
hospital readmissions, patient readmission, discharge, discharge medications, medication 
programs, and follow-up. The reference lists for systematic reviews of related studies were 
reviewed for additional relevant articles. The criterion that was included was any program where 
medications were given to patients upon discharge from an acute setting and outcomes related to 
hospital readmissions. All study designs were included in the search. Studies written in English 
but completed in a country outside of the US were also included. Article exclusion criteria were 
studies with participants less than 18 years of age and research that did not discuss outcomes on 
readmission rates from an acute setting. The search was limited to the past 5-years of 
publication. The number of studies examining readmission rates among those discharged from an 
inpatient psychiatric unit who received a 30-day filled prescription of their medications is 
limited; therefore, the literature review included all programs in which individuals who received 
medications in an acute setting were used to determine how the program affected 30-day 
readmissions. 
Review of Literature 
Upon completion of a literature review, there were a limited number of studies found that 
examined 30-day readmission rates after providing medication assistance upon discharge. 
Tomko et al. (2013) completed a 12-month retrospective study including 504 adult hospitalized 
psychiatric patients over the age of 18. Depending on their medication coverage and risk for 
suicidality, the patients were provided a 30-, 15-, or 7-day supply of psychiatric medications 
coupled with pharmacist-led medication counseling. The patients who were without health 
insurance, which accounted for less than 2% of the study participants, were given a 14-day filled 
prescription funded by charitable donations. The hospital pharmacy filled and delivered the 
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medications to the psychiatric unit before the patient was discharged. In addition, the pharmacist 
met with the patient individually on the day of discharge to discuss medication identification and 
uses, potential side effects, and management of side effects. Thirty-day hospital readmissions 
were significantly reduced in the study group compared to total readmissions (Tomko et al., 
2013) 
 Akerle et al. (2017) reported a 27% reduction in 30-day psychiatric readmissions when 
patients participated in an intervention program to improve the transition from inpatient care to 
outpatient follow-up services. This retrospective study included 1,707 patients from an inpatient 
psychiatric unit and was evaluated over a period of 12 months. The patients, aged 18 to 65 years, 
had their medications delivered from the pharmacy to the psychiatric unit on the day of 
discharge. The patients were responsible for the cost of their medications. An additional 
component of this program included a follow-up phone call to the patient within 72 hours of 
discharge. The purpose of the telephone call was to assess clinical status, medication review, and 
an understanding for aftercare, including scheduled appointments. The patient was also offered a 
patient navigator to follow their progress for 30-days post-discharge. The patient navigator 
provided information on community based services, telephone calls 24 hours prior to their first 
outpatient appointment, weekly phone calls to check in, and problem solving assistance within 
the 30-days post discharge (Akerle et al., 2017).  
 In a study by Blee, Roux, Gautreaux, Sherer and Garey (2015), free inhalers were 
provided to uninsured patients diagnosed with chronic obstructive pulmonary disease (COPD) on 
the medical units. This study implemented a multidose medication dispensing on discharge 
service and compared the readmission rates prior to implementing these services. The study was 
planned to be implemented over a 12-month period but due to a substantial decline in 
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readmissions, the study was stopped early. Hospital pharmacists were notified of patients who 
were admitted and prescribed COPD medications. The pharmacists then provided counseling to 
patients on their COPD medication within 48 hours of discharge. 
 A fourth study by Comer et al. (2017) found that by offering a discharge prescription 
program to patients on medical units resulted in a 16% decrease in 30-day hospital readmissions 
over a 23-month period. Within 24-hours of admission to the unit, the patients were presented 
with the opportunity to participate in the program. Those who participated were able to pick up 
their filled medications as apart of their discharge process. Similar to Comer et al. (2017), 
Kirkham, Clark, Paynter, Lewis and Duncan (2014) completed a 24-month retrospective study in 
which participating patients were delivered their medications to the medical unit hours prior to 
discharge. However, in this study, the hospital pharmacist provided the patients follow-up phone 
calls within 72 hours of discharge. The pharmacist assessed compliance, problems, and 
understanding of the medications they were discharged on. The patients who participated in this 
study had lower rates (5%) of 30-day readmissions compared to those who received standard 
care (9.5%) (Kirkham et al., 2014). 
 The final study from the literature review was by Shull, Braitman, Stites, DeLuca, and 
Hauser (2018). This study resulted in a 10.6% reduction of 30-day readmissions by providing a 
Medication REACH (Reconciliation, Education, Access, Counseling, Healthy Patient at Home) 
Intervention compared to patients who did not participate. This intervention was completed over 
a 12-month period to patients on a medical unit. The average age of patients was 65 years old. 
The Medication REACH Intervention was a pharmacist-led program providing the patient with 
educational sessions while in the hospital, ensuring the prescription was ready for pickup at time 
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of discharge, providing the patient with a follow-up phone call within 72 hours of discharge, and 
offering the patient home visits (Shull et al., 2018). 
 In conclusion, all six studies found a reduction in 30-day readmission rates by providing 
patients with medications at discharge. Only two of the studies used medication assistance 
programs on psychiatric units. The other four studies were with patients discharged from medical 
units. In both of the studies with psychiatric hospitalizations, other support services were 
provided in addition to providing filled prescriptions upon discharge. One of the studies provided 
extensive outpatient support services to reduce 30-day readmissions (Akerle et al., 2017) and the 
other utilized pharmacy-led medication counseling in addition to providing filled prescriptions 
upon discharge (Tomko, et al., 2013). 
Project Aims 
The primary aim of this Quality Improvement (QI) project was to determine if the 
Discharge Medication Assistance Program (DMAP) at CoxHealth in Springfield, Missouri 
reduced the 30-day readmission rates on three inpatient psychiatric units. 
Project Questions 
1. Do patients discharged from the adult and senior adult psychiatric units at CoxHealth who 
participated in the DMAP program have a lower incidence of 30-day readmission rates than 
those discharged from the adult psychiatric units at CoxHealth who didn’t participate in DMAP 
during the same time frame? 
2. What are the demographic characteristics (age and gender) and discharge diagnoses of those 
patients who were discharged on DMAP and were readmitted to the adult and senior adult 
inpatient psychiatric units within 30-days? 
Theoretical Framework 
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 The theoretical framework that guided this project was the Donabedian Model. Avedis 
Donabedian developed the Model in 2005, which is a model to improve patient outcomes by 
improving clinical processes. Three processes are used to evaluate the quality of healthcare—
structure, process, and outcome (Donabedian, 2005). The Donabedian Model has been found to 
be a useful framework in QI projects. 
 Donabedian defines the structures as the physical and organizational healthcare settings 
where care takes place (Donabedian, 2005). In this case, the setting was the two inpatient adult 
psychiatric units and one senior adult psychiatric unit at CoxHealth. The processes are defined as 
the mechanisms, service, or intervention of the care being delivered (Donabedian, 2005). In this 
project, the process was the provision of a 30-day supply of medication upon discharge (DMAP), 
from two adult and one senior adult inpatient psychiatric unit for patients who had no health 
insurance. In addition, the process of nurse-provided medication education upon discharge to 
ensure the patient understands the times, dosages, and reason for taking the medication is 
completed. The final component of the Donabedian Model are the outcomes. Outcomes are 
defined as the recovery or rebuilding of condition or function (Donabedian, 2005). The outcome 
of this project was the 30-day readmission rates to the inpatient psychiatric units. The 
Donabedian Model has also been used in other studies, including projects assessing 30-day 
readmission rates after implementing improved communication techniques (Marteniz et al., 
2018) and for chronic obstructive pulmonary disease management programs (Henry, Man, & 
Fung, 2013). 
Methodology 
Design 
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The design of this QI project was a retrospective review of the discharge data from the 
EHRs of patients discharged from three CoxHealth psychiatric units. Descriptive statistics were 
completed to compare data and evaluate the demographics.  
Institutional Review Board 
Approval for this QI project was received from University of Kansas Medical Center 
(KUMC) Institutional Review Board (IRB). Once approved by KUMC, the project was 
submitted to the Human Rights and Protection Council (HRPC) at CoxHealth. The HRPC at 
CoxHealth requested that KUMC act as the primary IRB. The project began when both 
approvals were authorized. This project was considered exempt status since it was a minimal 
risk, non-interventional, chart review without human participants. The de-identified report was 
kept on a password-protected computer and emailed to the primary investigator (PI) using 
KUMC’s Secure File Transfer. The Health Insurance Portability and Accountability Act 
(HIPPA) privacy guidelines for data sharing were followed. Upon project approval, collecting 
and analyzing the data was preformed through March 2019. 
Setting 
The setting for this project was three inpatient psychiatric units at CoxHealth. Managerial 
permission was given to the author by the Administrative Director of Psychiatric Services to 
conduct data collection on the psychiatric units at CoxHealth (Appendix C). CoxHealth is a not-
for-profit health system located in Springfield, Missouri. CoxHealth provides comprehensive 
healthcare services, including behavioral health and medical services. There are four psychiatric 
units at CoxHealth: A child/adolescent unit for children under age 18, two adult units ages 18 to 
49 years old, and a senior adult unit, ages 50 years and above.  
Sample 
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The sample for this project was the discharge data of those patients who were discharged 
from two adult inpatient psychiatric units and the senior adult unit at CoxHealth from January 
2018 through June 2018. The child and adolescent patients were excluded from the study 
because DMAP is specifically for patients aged 18 and older. 
Data Collection 
The author created an Excel spreadsheet (Appendix D) which included age, gender, 
discharge and readmission diagnosis, the unit they were discharged from (identified as “F200” 
[Adult II Inpatient Psychiatry Unit], “F300” [Adult I Inpatient Psychiatry Unit], or “C200” 
[Senior Adult Inpatient Psychiatry Unit]) and the number of days between discharge and 
readmission for each DMAP patient. Permission to access the de-identified data to make 
comparisons was approved (Appendix E), which allowed the CoxHealth Data Analytics to 
complete the retrospective report, enter the data into the Excel spreadsheet (Appendix D), and 
provide it to the author. 
Data Analysis 
Upon receiving the de-identified report, the project was evaluated to determine if DMAP 
participation reduced the 30-day readmission rates on the three CoxHealth inpatient psychiatric 
units by comparing the discharge and readmission rates of all patients from the three inpatient 
units with those of the DMAP patients. Descriptive statistics were calculated as the percentage of 
total 30-day psychiatric readmissions, which were compared to the percentage of 30-day 
psychiatric readmissions for DMAP participants. 
The gender of patients who received DMAP and was readmitted was calculated as a 
percentage. The age range of individuals discharged on DMAP and readmitted within 30-days 
was calculated and presented as means and in interval categories. Psychiatric readmissions were 
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categorized according to the unit the patient was discharged from. The discharge and readmitting 
diagnoses were analyzed and arranged based on the frequency of diagnoses seen upon discharge. 
Finally, the days between discharge and readmission were provided as a range and mean for 
every readmitted patient. This information is presented in a table format. 
Results 
The purpose of this quality improvement project was to evaluate the 30-day readmission 
rates of patients who participated in the Discharge Medication Assistance Program (DMAP) 
upon discharge from the adult and senior adult inpatient psychiatric units at CoxHealth in 
Springfield, Missouri. The number of readmission rates of DMAP patients were compared to 
non-DMAP patients discharged over a 6-month period from January 1, 2018 to June 30, 2018. 
The following section presents the findings from the two research questions. 
Research Question 1 
The first research question in this QI project was, Do patients who were discharged on 
DMAP from the adult and senior adult psychiatric units have a lower 30-day readmission rate 
than those who were not discharged on the DMAP from the same adult and senior adult 
psychiatric units during the same time frame? 
Analysis of all discharges from the three inpatient psychiatric units at CoxHealth during 
the 6-month period revealed that patients who were discharged on DMAP had lower readmission 
rates than patients who did not participate in DMAP. During the 6-month period between 
January 1, 2018 and June 30, 2018, there were a total of 1,495 discharges from the three 
inpatient psychiatric units. During this period there were a total of 221 (14.8%) patients 
readmitted within 30-days of their discharge. Out of the total readmissions during this time 
period, 19 (1.3%) were discharged on DMAP and 202 (13.5%) were discharged without DMAP. 
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The patients who were discharged without the DMAP had a 12% higher readmission rate than 
those patients who were discharged on the DMAP (See Table 1). In conclusion, the patients who 
were discharged on DMAP had a lower 30-day readmission rate than those who did not 
discharge on the DMAP from the same psychiatric units and during the same time frame. 
Research Question 2 
 The second research question in this QI project was, What were the demographic 
characteristics (age and gender) and discharge diagnoses of those patients who were discharged 
on the DMAP and readmitted to either the adult or senior adult inpatient psychiatric unit within 
30-days of discharge?   
The majority of the DMAP patients who were readmitted within 30 days of discharge 
were men in the age range between 20 and 39 years (See Table 2).  Of the 19 DMAP patients 
readmitted within 30-days of discharge, the most common discharge diagnosis was major 
depressive disorder (MDD) (52.6%). Four of the readmitted DMAP patients (21.1%) had a 
discharge diagnosis of a substance related disorder, and three patients (15.8%) had a discharge 
diagnosis of bipolar disorder. Two other diagnoses at discharge were adjustment disorder and 
poisoning by antiparkinsonism drugs or other central muscle-tone depressant, intentional self-
harm (See Table 3). 
The range of days between discharge and readmission for the 19 DMAP patients was 1 to 
28 days with an average of 12.2 days. Table 3 provides the discharge and readmitting diagnosis 
of the 19 DMAP patients, along with the number of days between discharge and readmission.  
Of the DMAP patients who were readmitted, 17 patients were discharged from the two adult 
psychiatric units and only two patients were discharged from the Senior Adult Unit. 
Discussion 
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This quality improvement study used the framework of the Donabedian Model to 
evaluate the impact of DMAP on psychiatric readmission rates at CoxHealth. With psychiatric 
readmissions rates on the rise, CoxHealth began taking efforts to implement DMAP. The 
purpose of implementing DMAP in 2013 was to provide uninsured patients a 30-day supply of 
their prescribed medications upon discharge with the outcome objective to reduce psychiatric 
readmissions. The staff at CoxHealth had never evaluated the success of this program. The 
administrative directors of the psychiatric units requested the author to conduct this evaluation of 
DMAP. 
The DMAP was created to support patients who did not have health insurance and could 
not afford to purchase their psychiatric medications at discharge. Although the DMAP patients 
received their medications upon discharge, 1.3% of these patients were readmitted to the 
psychiatric hospital within 30-days over a 6-month period. Therefore, it can be surmised that 
other variables besides a lack of access to medications accounted for the DMAP patient 
readmissions. Due to the fact the author was unable to directly access the medical records of the 
patients who were readmitted within 30 days after discharge, it was difficult to investigate 
possible factors that contributed to the readmissions.  
 The author was able to obtain the diagnoses of those discharged and readmitted within 30 
days. The majority of discharge and readmitting diagnoses in this project were major depressive 
disorders (MDD). Substance related disorders accounted for 21.1% of the discharge and 10.5% 
of the readmitting diagnoses. Patients with substance related disorders often have co-occurring 
diagnoses, including major depressive and personality disorders. These patients also face barriers 
transitioning into outpatient treatment programs upon discharge (Mojtabi, Chen, Kaufmann, & 
Crum, 2014), which is especially true for uninsured patients. 
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The majority of DMAP patients being readmitted were younger men. Variables that can 
play a factor in psychiatric readmissions may include age, gender, race, psychiatric diagnosis, 
history of incarceration, history of alcohol/drug abuse, number of previous inpatient 
hospitalizations, type of insurance, length of stay of admission, housing status, legal status 
(voluntary/involuntary), medication compliance, and availability of social support (Lorine et al., 
2015). Fewer senior adult readmissions may have resulted from the fact that senior adults qualify 
for insurance benefits (Medicare), minimizing barriers to aftercare services. This protective 
factor may have contributed to fewer readmission compared to the adult units. In addition, the 
differences in readmissions between the adult and senior adult units could have been attributed to 
methods of discharge planning between the units. Finally, the variances between the units’ 
readmission rates may be a reflection of staff experience and knowledge of available community 
resources. 
 The findings from this project and other studies in the literature support evidence that 
providing psychiatric patients with discharge medications can reduce hospital readmission rates. 
In the study by Tomko et al. (2013), 30-day hospital readmissions were significantly reduced in 
psychiatric patients who were provided their psychiatric medications, coupled with pharmacist-
led medication counseling. In the Akerle et al. (2017) study, there was a 27% reduction in 30-day 
psychiatric readmissions when patients participated in an intervention program to improve the 
transition from inpatient care to outpatient follow-up services. In addition to the patients 
medications delivered from the pharmacy to the psychiatric unit on the day of discharge, this 
program included follow-up phone calls to the patient within 72 hours of discharge. A distinction 
in this study was the patients were offered a patient navigator to follow their progress for 30-days 
post-discharge (Akerle et al., 2017).  
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 Both of the studies by Tomko et al. (2013) and Akerle et al. (2017) were similar to 
DMAP in that the patients were provided their medications upon discharge and received 
counseling from a health provider about medication management. However, in the Tomko et al. 
and Akerle et al. studies, patients received pharmacist-led medication counseling whereas in the 
DMAP program at CoxHealth registered nurses were responsible for this education. In addition, 
the patients in the Akerle et al. study were responsible for the cost of their medications whereas 
in DMAP the medications are provided for free. The Tomko et al. study had a mixed sample 
where some of the patients had health insurance and some did not. The DMAP is unique from 
the other studies reviewed in that all of the patients were without health insurance. Uninsured 
patients tend to have more complicated risk factors and research has found that patients without 
health insurance have a higher risk of hospital readmission (Hamilton et al., 2016). 
The Akerle et al. (2013) study provided extensive aftercare support interventions that are 
lacking in the DMAP. The utilization of a patient navigator, as noted in the Akerle et al. study 
may be an important consideration when providing patient support after inpatient discharge. In 
addition, establishing collaboration with a community mental health center would provide 
addition services to patients upon discharge. Collectively, the participant would benefit not only 
by receiving their medications upon discharge, but would also have access to patient navigators 
once discharged from the inpatient psychiatric unit. 
Strengths 
 This student researcher is a nurse employed at CoxHealth and has a relationship with the 
staff on the units where the data was collected. The student researcher was able to meet with the 
Administrative Director of Psychiatric Services along with the nursing research coordinator at 
CoxHealth to develop a quality improvement project focused on improving DMAP in the service 
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of reducing 30-day psychiatric patient readmission. This author has a working understanding of 
how the DMAP is organized and implemented. 
Limitations 
 There were several limitations associated with this quality improvement project. The 
HRPC at CoxHealth would not allow this student researcher direct access to the DMAP medical 
records due to their policies governing protected patient health information. A member of the 
Business Analyst Department at CoxHealth was assigned to provide the discharge data for 
analysis, which limited the opportunity to explore factors contributing to patient readmissions. 
Second, hospital readmissions were accounted for only at CoxHealth and it is not known whether 
any DMAP patients were readmitted to another psychiatric hospital within a 30-day period.  
 Another limitation was that the data analysis was for patients discharged during a 6-
month period. A longer data analysis period would result in more information to reflect relevant 
discharge and readmission patterns on the psychiatric units at CoxHealth. An assumption about 
DMAP is that providing psychiatric patients free medications upon discharge would reduce 30-
day hospital readmission rates. While this program showed a reduction in readmissions, there 
were DMAP patients who return within 30-day. Other factors for readmissions to be considered 
are social determinants, such as living situation and social support. Without access to patient’s 
the medical record, these factors cannot be correlated with the causes for early readmissions. 
Clinical Implications 
 Clinical implications from the findings of this study are evidence of a need for further 
explorations of the factors that contributed to a less than 30-day psychiatric readmission for those 
patients who received DMAP. The DMAP patients were discharged with a 30-day supply of 
their prescribed medications; therefore, it is unlikely that a lack of access to medications is a 
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reason for readmission. Determining the reason(s) for hospital readmission would require a 
further examination of the variables, including possible social determinants that contribute to 
readmissions. The development of future quality improvement projects in an effort to reduce 
psychiatric readmissions may be warranted if a deeper analysis of 30-day readmissions is 
recorded. 
 Clinical implications may include a need for continued monitoring and evaluation of the 
data related to the 30-day readmission rates of the DMAP patients. When DMAP was developed, 
the goal was to decrease both psychiatric and medical readmissions by 20%. In order to evaluate 
a decrease in hospital readmissions, collecting data over a larger time frame along with assessing 
medical readmissions would be suggested. If the number of readmissions continues to decrease, 
this data could support additional grant funding or assistance from various CoxHealth 
foundations to further support the DMAP program. If there is a 12% decrease in psychiatric 
readmissions in DMAP patients compared to non-DMAP patients, the cost savings could fund 
additional case management staff. Additionally, case management services can ensure that 
patients have appropriate psychiatric follow-up and longer-term access to medications. Case 
management meetings among these three units to discuss community resources for follow-up 
could potentially benefit to further decrease readmission rates. 
The patient assistance studies in the literature provided additional intensive outpatient 
follow-up services to further decrease 30-day readmissions. Interventions included follow-up 
phone calls, medication reconciliation by a pharmacist, patient-centered education about their 
medication(s), collaboration with healthcare providers, and follow-up with the patient at home as 
needed may be considered as a future implication to improve practice and decrease hospital 
readmissions at CoxHealth. The results of this project, interventions from the literature, and 
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recommendations to further reduce psychiatric readmissions will be presented to the CoxHealth 
Administrative Director of Psychiatric Services and program staff. There will be an emphasis on 
sharing information with case management who are primarily responsible for discharge planning. 
Providing a presentation of this project and information gleaned from literature may improve the 
delivery of healthcare at CoxHealth while further reducing psychiatric readmissions and 
improving patient outcomes.  
Conclusion 
 Programs focusing on high-risk populations are being implemented to help reduce costly 
readmission rates. Patients without health insurance are more prone to experience barriers to 
follow-up care. Identifying ways to overcome these barriers is vital in decreasing potential for 
readmissions. Medication assistance upon discharge has been found to reduce hospital 
readmissions. Interventions that have also been used include follow-up phone calls, home visits, 
access to hospital pharmacists, and collaboration with outpatient providers. All the 
aforementioned could be utilized by inpatient psychiatric facilities, including CoxHealth to 
further reduce readmission rates. This project was completed to determine the impact of DMAP 
on 30-day readmission rates to three inpatient psychiatric unit at CoxHealth. Incorporating 
additional interventions with medications upon discharge may be a prospective solution to the 
continuation of minimizing readmissions. 
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Table 1 
DMAP Participant Readmission Information 
30-day Readmission Rates Between 1/1/18-6/30/18 Frequency/Percentage 
Total discharges 
(n=1,495) 
Total readmissions 
DMAP readmissions 
Non-DMAP readmissions 
221 (14.8%) 
19 (1.3%) 
202 (13.5%) 
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Table 2 
Demographic of Readmitted DMAP Patients  
 
 
 
  
Demographics (N=19) 
Frequency/ 
Percentage 
Total discharges 
(n=1,495) 
Gender of DMAP patients readmitted within 30-days  16 (84.2%) male 
3 (15.8%) female 
 
 
 
Range 
Age range of DMAP patients readmitted within 30-days 6 (32%) 
8 (42.1%) 
3 (15.7%) 
2 (10.5%) 
20-29 
30-39 
40-49 
50-59 
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Table 3 
Primary Discharge and Readmitting Diagnosis of the DMAP Patients (N=19) and Number of 
Days between Discharge and Readmission 
Primary Discharge Diagnosis Readmission Primary Diagnosis 
# of days between 
discharge and 
readmission 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
Bipolar 
Bipolar 
Bipolar 
Alcohol Dependence 
Substance Abuse Disorder 
Substance Abuse Disorder 
Substance Abuse Disorder 
Adjustment Disorder1 
Poisoning by antiparkinsonism 
drugs or other central muscle-tone 
depressant, intentional self-harm 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
MDD 
Alcohol Dependence 
Bipolar 
Bipolar 
Schizoaffective Disorder* 
Alcohol Dependence 
Adjustment Disorder2 
MDD 
MDD 
MDD 
MDD 
 
 
1 
1 
1 
5 
6 
9 
11 
19 
23 
1 
23 
24 
19 
24 
1 
9 
22 
28 
6 
Note. MDD=Major Depressive Disorder, with- or without psychosis or unspecified; Substance 
Abuse Disorder includes stimulant abuse with stimulant included psychiatric disorder with 
hallucinations or with mood disorder; Adjustment Disorder1=Adjustment disorder with mixed 
disturbance of emotions and conduct; Adjustment Disorder2=Adjustment disorder with mixed 
anxiety and depressed mood; Schizoaffective Disorder*=Schizoaffective disorder, bipolar type. 
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Appendix A 
Discharge Medication Assistance Program (DMAP) Form 
           
COXHEALTH PSYCHIATRIC SERVICES 
DISCHARGE MEDICATION ASSISTANCE PROGRAM (DMAP) FUND 
Authorization form for Discharge Medication Purchase 
(Fax completed form to Convenient Care Pharmacy North 69-8888) 
Approval Guidelines: 
• The Medication Assistance fund is for self-pay inpatients that have no resources to purchase 
needed prescription medications. Purchases by this fund should always be as a last resort. 
• Outpatients and patients being discharged from the ED do not qualify for assistance through 
this program. 
• Antibiotics are filled in full. Other medication may be filled up to a 30-day supply – no 
refills. Generics will be used when possible. No controlled substances are eligible. 
• This fund will not cover co-pays, over-the-counter or pre-admission medications. 
• Patient has not accessed this fund in 90 days. Patient has not accessed this fund more than 3 
times. 
 
Date of Request: _______Patient Name: _________________________DOB: ______________ 
Address: ____________________________City: __________________State: _____Zip: ______ 
Phone#: ____________________ Primary DX: _______________________________________ 
 
Confirm all of the following before authorizing purchase by the Medication Assistance 
Fund: 
 Patient has no coverage of any kind for medications. In addition to having no payment 
sources, all possible alternative methods for decreasing cost or obtaining this 
medication have been exhausted. Examples of alternatives to use of this fund include: 1) 
generic substitution, 2) talk with unit pharmacist to get a recommendation for a less costly 
equivalent medication 3) Online coupons. 
Resources Contacted:  
1.   
2.   
3.   
 HumanArc has screened and found patient not eligible for Medicaid, proceed with 
authorization. 
1. If not screened yet, refer to HumanArc – do not authorize. 
2. CCP will accept Medicaid pending as a payer source. (Utilize Medicaid Pending 
Med Authorization form) 
 Patient’s FPL is 200% or less. If not, patient does not qualify for assistance. Do not 
authorize. 
Number of people living in household: _______ Total monthly income: $____________  
or Annual income: $___________________ 
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200% Federal Poverty Levels (FPL) 
Household Size Monthly Income Limit Annual Income Limit 
1 $1,915 $22,980 
2 $2,585 $31,020 
3 $3,255 $39,060 
4 $3,925 $47,100 
 Patient referred to CMAP for chronic medication assistance. 
 Outpatient referral for ongoing medication follow up: ___________________________     
          (name of provider) 
 
Patient Name:______________________                       Anticipated Discharge Time:________  
 
Authorized Medications: 
Discharging Medication Dosage Quantity Price 
DMAP formulary is $5. All 
other meds call CCP for pricing
Patient Co-Pay 
(Suggested not 
required) 
1. 
 
  $  
2. 
 
  $  
3. 
 
  $  
4. 
 
  $  
5. 
 
  $  
6. 
 
  $  
7. 
 
  $  
 
Total 
$  
   
 F1   F2 F3 C2 MSW Phone:_____________________   Fax:_____________ 
            (circle unit) 
 
   MSW Approval only (up to 5 medications maximum or $30 total maximum):    
  Signature:  ___________________________ Print Name: ___________________________ 
 
    Unit Manager/AUM Approval (6 medications or more up to $150):  
 Signature:  __________________________ Print Name:  ____________________________ 
 
   Administrative Director Approval (Total price greater than $150):   
  Signature: ________________________     Print Name: _____________________________ 
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Appendix B 
Medications Covered by DMAP 
DMAP FORMULARY 
Tier 1     
Updated 8-18-2017   
    
Quantity 
Authorized 
Allergies/Cold and Flu 
Benzonatate 100mg cap   15 
Benzonatate 200mg cap   15 
Cetiriizine 10mg tab   30 
Loratadine 10mg tab   30 
Promethazine DM syrup   180mL 
      
Antibiotics   
Amoxicillin 250mg cap   30 
Amoxicillin 500mg cap   30 
Cephalexin 250mg cap   30 
Cephalexin 500mg cap   30 
Ciprofloxacin 250mg tab    20 
Ciprofloxacin 500mg tab   20 
Penicillin VK 250mg tab   28 
Penicillin VK 500mg tab   14 
SMZ-TMP 400mg-80mg tab    30 
SMZ-TMP DS 800mg-160mg tab   20 
      
Antifungals   
Fluconazole 150mg tab   1 
Terbinafine 250mg tab   30 
      
Antivirals     
Acyclovir 200mg cap    30 
Acyclovir 400mg cap    30 
Acyclovir 800mg cap    15 
      
Arthritis/Pain   
Allopurinol 100mg tab   30 
Allopurinol 300mg tab   15 
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Baclofen 10mg tab   30 
Cyclobenzaprine 5mg tab    30 
Cyclobenzaprine 10mg tab    30 
Diclofenac DR 50mg tab   15 
Diclofenac DR 75mg tab   15 
Ibuprofen 400mg tab   60 
Ibuprofen 600mg tab    60 
Ibuprofen 800mg tab    30 
Indomethacin 25mg cap   30 
Indomethacin 50mg cap   15 
Meloxicam 7.5mg tab   30 
Meloxicam 15mg tab    30 
Naproxen 375mg tab   60 
Naproxen 500mg tab   60 
Prednisone 2.5mg tab    30 
Prednisone 5mg tab    30 
Prednisone 10mg tab    30 
Prednisone 20mg tab    15 
      
Asthma     
Albuterol 0.083% nebulizer soln (25x3ml 
vials)   75 
      
Cholesterol   
Gemfibrozil 600mg tab   30 
Lovastatin 10mg tab   30 
Lovastatin 20mg tab   30 
Lovastatin 40mg tab   30 
Pravastatin 10mg tab   10 
Pravastatin 20mg tab    10 
Pravastatin 40mg tab   7 
Simvastatin 5mg tab   30 
Simvastatin 10mg tab   30 
Simvastatin 20mg tab   30 
Simvastatin 40mg tab   30 
Simvastatin 80mg tab   30 
      
Diabetes     
Glimepiride 1mg tab   30 
Glimepiride 2mg tab    30 
Glimepiride 4mg tab   15 
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Glipizide 5mg tab    30 
Glipizide 10mg tab   30 
Glyburide 2.5mg tab   30 
Glyburide 5mg tab   15 
Glyburide/Metformin 2.5mg/500mg tab   30 
Metformin 500mg tab    90 
Metformin 850mg tab   60 
Metformin 1000mg tab   60 
Metformin 500mg ER tab   60 
      
External     
Lidocaine 2% viscous solution (100mL 
bottle)    100mL 
      
GI     
Dicyclomine 10mg cap    60 
Dicyclomine 20mg tab    60 
Famotidine 20mg tab    30 
Famotidine 40mg tab    30 
Lactulose syrup    240mL 
Loperamide 2mg cap   15 
Metoclopramide 10mg tab    60 
Omeprazole 20mg cap   30 
Omeprazole 40mg cap   15 
Prochlorperazine 10mg tab   30 
Promethazine 25mg tab   30 
Ranitidine 150mg tab   60 
Ranitidine 300mg tab   30 
      
Eyes       
Gentamicin 0.3% op. soln (5ml bottle)   5mL 
Timolol Maleate 0.25% op. soln (5ml bottle)   5mL 
Timolol Maleate 0.5% op soln (5ml bottle)   5mL 
      
Heart/Blood Pressure 
Amiodarone 200mg tab   30 
Amlodipine 2.5mg tab   30 
Amlodipine 5mg tab   30 
Amlodipine 10mg tab   30 
Atenolol 25mg tab    30 
Atenolol 50mg tab   30 
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Atenolol 100mg tab    30 
Atenolol-Chlorthalidone 100mg/25mg   15 
Benazepril 20mg tab   30 
Benazepril 40mg tab   30 
Bisoprolol-HCTZ 5mg-6.25mg tab    30 
Bisoprolol-HCTZ 10mg-6.25mg tab    30 
Carvedilol 3.125mg tab   60 
Carvedilol 6.25mg tab   60 
Carvedilol 12.5mg tab   60 
Carvedilol 25mg tab   60 
Cilostazol 100mg tab   30 
Clonidine 0.1mg tab    30 
Clonidine 0.2mg tab   30 
Clonidine 0.3mg tab   30 
Diltiazem 60mg tab    15 
Diltiazem 90mg tab   15 
Diltiazem 120mg tab    15 
Enalapril 20mg tab   15 
Enalapril-HCTZ 10mg-25mg tab   30 
Flecainide 50mg tab   15 
Furosemide 20mg tab    30 
Furosemide 40mg tab   30 
Furosemide 80mg tab    30 
Guanfacine 1mg tab    30 
Guanfacine 2mg tab    30 
Hydralazine 10mg tab    30 
Hydralazine 25mg tab    30 
Hydrochlorothiazide(HCTZ)12.5mg cap   30 
Hydrochlorothiazide (HCTZ) 25mg tab   30 
Hydrochlorothiazide (HCTZ) 50mg tab   30 
Isosorbide Mononitrate 30mg ER tab   15 
Isosorbide Mononitrate 60mg ER tab   15 
Lisinopril 2.5mg tab    30 
Lisinopril 5mg tab   30 
Lisinopril 10mg tab   30 
Lisinopril 20mg tab   30 
Lisinopril-HCTZ 10mg-12.5mg tab    30 
Lisinopril-HCTZ 20mg-12.5mg tab   30 
Lisinopril-HCTZ 20mg-25mg tab   30 
Methyldopa 250mg tab   30 
Metoprolol Tartrate 25mg tab   60 
 41
Metoprolol Tartrate 50mg tab   60 
Metoprolol Tartrate 100mg tab   60 
Prazosin HCL 1mg cap   15 
Propranolol 10mg tab    30 
Propranolol 20mg tab    15 
Propranolol 40mg tab    15 
Quinapril 10mg tab   30 
Quinapril 20mg tab   30 
Quinapril 40mg tab   30 
Sotalol HCL 80mg tab   30 
Sotalol HCL 120mg tab   30 
Spironolactone 25mg tab   30 
Spironolactone 50mg tab   15 
Terazosin 1mg cap    30 
Terazosin 2mg cap   30 
Terazosin 5mg cap   30 
Terazosin 10mg cap    30 
Torsemide 5mg tab   30 
Torsemide 10mg tab   30 
Torsemide 20mg tab   30 
Triamterene-HCTZ 37.5mg-25mg tab   15 
Triamterene-HCTZ 75mg-50mg tab    15 
Verapamil 80mg tab   30 
Verapamil 120mg tab   30 
Verapamil ER 120mg tab   15 
Verapamil ER 180mg tab   15 
Verapamil ER 240mg tab   15 
Warfarin 1mg tab    30 
Warfarin 2mg tab    30 
Warfarin 2.5mg tab   30 
Warfarin 3mg tab    30 
Warfarin 4mg tab    30 
Warfarin 5mg tab   30 
Warfarin 6mg tab    30 
Warfarin 7.5mg tab    30 
Warfarin 10mg tab   30 
      
Mental Health   
Amitriptyline 10mg tab    30 
Amitriptyline 25mg tab   15 
Amitriptyline 50mg tab   5 
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Amitriptyline 75mg tab    5 
Benztropine 0.5mg tab   30 
Benztropine 1mg tab   30 
Benztropine 2mg tab   30 
Bupropion SR 100mg tab   10 
Bupropion SR 150mg tab   10 
Bupropion XL 150mg tab   10 
Bupropion XL 300mg tab   5 
Buspirone 5mg tab   60 
Buspirone 10mg tab   60 
Buspirone 10mg tab   30 
Carbamazepine 100mg chew tab   15 
Carbamazepine 200mg tab   10 
Citalopram 20mg tab   30 
Citalopram 40mg tab   30 
Divalproex DR 250mg tab   60 
Divalproex DR 500mg tab   30 
Escitalopram 5mg tab   30 
Escitalopram 10mg tab   30 
Escitalopram 20mg tab   30 
Fluoxetine 10mg tab   30 
Fluoxetine 10mg cap   30 
Fluoxetine 20mg cap    30 
Fluoxetine 40mg cap   15 
Fluvoxamine 25mg tab   15 
Gabapentin 100mg cap   90 
Gabapentin 300mg cap   60 
Gabapentin 400mg cap   30 
Guanfacine 1mg tab   60 
Guanfacine 2mg tab   30 
Haloperidol 0.5mg tab   15 
Haloperidol 1mg tab   10 
Haloperidol 2mg tab   10 
Hydroxyzine HCl 10mg tab   30 
Hydroxyzine HCl 25mg tab   30 
Hydroxyzine Pam 50mg tab   30 
Hydroxyzine Pam 25mg cap   60 
Hydroxyzine Pam 50mg cap   60 
Lamotrigine 25mg tab   60 
Lamotrigine 100mg tab   60 
Lamotrigine 150mg tab   60 
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Lamotrigine 200mg tab   30 
Levetiracetam 250mg tab   30 
Levetiracetam 500mg tab   30 
Lithium Carbonate 300mg cap   90 
Mirtazapine 15mg tab   10 
Mirtazapine 30mg tab   10 
Mirtazapine 45mg tab   10 
Nortriptyline 10mg cap   30 
Nortriptyline 25mg cap   30 
Nortriptyline 50mg cap   30 
Olanzapine 2.5mg tab   30 
Olanzapine 5mg tab   30 
Olanzapine 10mg tab   15 
Olanzapine 15mg tab   10 
Olanzapine 20mg tab   10 
Oxcarbazepine 150mg tab   30 
Oxcarbazepine 300mg tab   15 
Paroxetine 10mg tab   30 
Paroxetine 20mg tab   30 
Paroxetine 30mg tab   30 
Paroxetine 40mg tab   30 
Pramipexole 0.125mg tab   30 
Pramipexole 0.25mg tab   30 
Pramipexole 0.5mg tab   30 
Pramipexole 1mg tab   30 
Pramipexole 1.5mg tab   30 
Primidone 250mg tab   30 
Primidone 50mg tab   15 
Prochlorperazine 10mg tab    30 
Quetiapine 25mg  tab   30 
Quetiapine 50mg  tab   15 
Quetiapine 100mg  tab   15 
Quetiapine 200mg  tab   15 
Quetiapine 300mg tab    10 
Quetiapine 400mg tab    7 
Risperidone 0.5mg tab   30 
Risperidone 1mg tab   30 
Risperidone 2mg tab   10 
Risperidone 3mg tab   15 
Ropinirole 0.25mg tab   30 
Ropinirole 0.5mg tab   30 
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Ropinirole 1mg tab   30 
Ropinirole 2mg tab   30 
Ropinirole 3mg tab   30 
Ropinirole 4mg tab   30 
Sertraline 25mg tab   30 
Sertraline 50mg tab   30 
Sertraline 100mg tab   30 
Topiramate 25mg tab   60 
Topiramate 50mg tab   60 
Topiramate 100mg tab   30 
Topiramate 200mg tab   30 
Trazodone 50mg tab    30 
Trazodone 100mg tab   30 
Trazodone 150mg tab    30 
Trihexyphenidyl 2mg tab    60 
Trihexyphenidyl 5mg tab    30 
Venlafaxine 25mg tab   15 
Venlafaxine 50mg tab   15 
Venlafaxine 75mg tab   15 
Venlafaxine XR 75mg cap   15 
Venlafaxine XR 150mg cap   15 
Zonisamide 25mg cap   30 
Zonisamide 50mg cap   15 
Zonisamide 100mg cap   15 
      
Skin       
Hydrocortisone 1% cream (28.35-30g tube)   30gm 
Hydrocortisone 2.5% cream (30gm tube)   30gm 
Triamcinolone 0.025% cream (15gm tube)   15gm 
Triamcinolone 0.1% cream (15gm tube)   15gm 
Triamcinolone 0.1% ointment (15gm tube)   15gm 
      
Thyroid       
Levothyroxine 25mcg tab    10 
Levothyroxine 50mcg tab    10 
Levothyroxine 75mcg tab    10 
Levothyroxine 88mcg tab    10 
Levothyroxine 100mcg tab     10 
Levothyroxine 112mcg tab    7 
Levothyroxine 125mcg tab   7 
Levothyroxine 137mcg tab    7 
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Levothyroxine 150mcg tab     7 
Levothyroxine 175mcg tab    7 
Levothyroxine 200mcg tab    7 
      
Urinary     
Oxybutynin 5mg tab    10 
Phenazopyridine 100mg tab    3 
Phenazopyridine 200mg tab    3 
      
Vitamins & Nutritional Health 
Folic Acid 1mg tab    30 
Mag 64 64mg tab    60 
Magnesium Oxide 400mg tab    30 
Prenatal Plus    30 
      
Women’s Health   
Estradiol 0.5mg tab     30 
Estradiol 1mg tab     30 
Estradiol 2mg tab    30 
MedroxyprogesteroneAcetate 2.5mg tab    30 
Medroxyprogesterone Acetate 5mg tab    30 
Medroxyprogesterone Acetate 10mg tab    30 
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